TAYMANS JILL M 4

4 · CRYO CELL INTERNATIONAL INC · Filed May 29, 2026

AI-generated summary of this filing

Updated May 29, 2026

Cryo-Cell (CCEL) CFO Jill Taymans Exercises Options

What Happened

Jill M. Taymans, VP Finance and Chief Financial Officer of Cryo-Cell International, reported an options exercise (code M) on May 28, 2026. She exercised options to acquire 7,500 shares at $3.10 per share (total $23,250) and a contemporaneous disposition of 7,500 derivative shares is also reported at $3.10 per share (total $23,250).

Key Details

Transaction date: 2026-05-28; Filing date: 2026-05-29 (Form 4 accession 0001193125-26-248432).
Prices and amounts: Acquired 7,500 shares @ $3.10 = $23,250; Disposed (derivative) 7,500 @ $3.10 = $23,250.
Transaction code: M = Exercise or conversion of a derivative security.
Shares owned after transaction: Not specified in the provided filing data.
Notable footnotes included in the filing:
- F1–F4: Various time-based vesting schedules for different option grants (annual or multi-tranche vesting dates).
- F5: A grant under the 2022 Stock Incentive Plan with three tranches that also require stock-price performance hurdles ($6, $8, $10 average closing price over 20 trading days) in addition to time-based vesting.
Timeliness: Filing appears timely (transaction 2026-05-28; Form 4 filed 2026-05-29).

Context

The filing shows both an acquisition by exercise and a simultaneous disposition of the same number of derivative shares at the same price. That pattern commonly reflects an exercise combined with an immediate sell-to-cover or broker-assisted cashless transaction to satisfy exercise cost/tax obligations, but the Form 4 does not state the exact mechanics. This is an options exercise report rather than an open-market buy or sale of already-owned common stock.

Form 4

Period: 2026-05-28

VP Finance, CFO

Transactions

Exercise/Conversion
Common Stock
2026-05-28$3.10/sh+7,500$23,250→ 52,896 total
Exercise/Conversion
Stock Option
2026-05-28$3.10/sh−7,500$23,250→ 0 total
Exercise: $3.10From: 2019-06-02Exp: 2026-06-02→ Common Stock (7,500 underlying)

Holdings

Stock Option
[F1]
Exercise: $8.00From: 2020-09-23Exp: 2027-09-23→ Common Stock (7,000 underlying)
7,000
Stock Option
Exercise: $4.62From: 2023-01-13Exp: 2028-01-13→ Common Stock (20,000 underlying)
20,000
Stock Option
[F2]
Exercise: $5.88From: 2023-12-22Exp: 2028-12-22→ Common Stock (10,000 underlying)
10,000
Stock Option
[F3]
Exercise: $7.35From: 2025-01-21Exp: 2030-01-21→ Common Stock (10,000 underlying)
10,000
Stock Option
[F4]
Exercise: $3.54From: 2026-01-07Exp: 2031-01-07→ Common Stock (10,000 underlying)
10,000
Stock Option
[F5]
Exercise: $3.54From: 2026-01-07Exp: 2031-01-07→ Common Stock (20,000 underlying)
20,000

Footnotes (5)

[F1]Stock options vest 1/5 per year commencing on September 23, 2020.
[F2]Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.
[F3]Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.
[F4]Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.
[F5]The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.

Signature

/s/ Jill Taymans|2026-05-29

1 file